GlassScriptPhysician profile
Hannah Cummins
NPI 1285301408
$5,243.37
in general payments reported to CMS, 2019-2025
36 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $409 · 2023: $1,106 · 2024: $1,958 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,722.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,158.16 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $813.70 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $700.32 | 2022-2025 | |
| Novo Nordisk INC | $448.79 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.96 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $226.38 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $182.52 | 2022-2025 | |
| Exact Sciences Corporation | $169.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $163.73 | 2022-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.68 | 2022-2024 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $112.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $106.08 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $62.26 | 2022 | |
| Glaxosmithkline, LLC. | $61.89 | 2022-2023 | Arexvy, Shingrix |
| Shield Therapeutics INC | $61.01 | 2023-2024 | Accrufer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $52.49 | 2022-2023 | |
| Hologic Sales and Service, LLC | $51.55 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Neurocrine Biosciences, INC. | $48.08 | 2024-2025 | Ingrezza |
| Tempus Ai, INC | $47.51 | 2024 | |
| Axsome Therapeutics, INC. | $47.23 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $44.22 | 2025 | Veozah |
| Edwards Lifesciences Corporation | $39.53 | 2025 | Sapien 3 Ultra Resilia |
| Paratek Pharmaceuticals, INC. | $32.63 | 2022-2023 | Nuzyra |
| Antares Pharma, INC. | $32.23 | 2023 | Xyosted, Tlando, Nocdurna |
| Idorsia Pharmaceuticals US INC | $29.40 | 2023 | Quviviq |
| Aimmune Therapeutics, INC. | $25.03 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $23.61 | 2022 | |
| Amneal Pharmaceuticals LLC | $21.18 | 2023 | Unithroid |
| Radius Health, INC. | $20.34 | 2025 | Tymlos |
| Sumitomo Pharma America, INC. | $19.26 | 2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $18.93 | 2025 | Edarbi |
| Ardelyx, INC. | $17.75 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $15.66 | 2024 | M-M-R II, Gardasil, Varivax |
| Lundbeck LLC | $13.66 | 2024 | Rexulti |
| Corium, LLC | $13.38 | 2022 | |
| Dynavax Technologies Corporation | $12.08 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Cummins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.